已经开发了一种新的催化系统,该系统使用高效的P-手性双膦-铑配合物与ZnCl 2作为催化剂的活化剂,对β-仲氨基酮进行不对称加氢。手性γ-仲氨基醇的产率为90-94%,对映选择性为90-99%,并且具有很高的周转率(最高2000 S / C; S / C =底物/催化剂比)。在NMR光谱和HRMS研究的基础上,已经提出了ZnCl 2对催化体系的促进作用的机理。该方法已成功应用于三种重要药物(S)-度洛西汀,(R)-氟西汀和(R)-atomoxetine,高收率且具有出色的对映选择性。
Process for preparing (+)trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine
申请人:——
公开号:US20040215020A1
公开(公告)日:2004-10-28
The present invention relates to a process for preparing (±)-trans-4-p-fluorophenyl-3-hyroxymethyl-1-methylpiperdine of formula (I). The present invention also relates to novel intermediates of the formula (IX) and (IX′) methods for preparing said intermediates and the use of said compounds for preparing Paroxetine and Omiloxetine.
1
A new catalytic system has been developed for the asymmetrichydrogenation of β‐secondary‐aminoketones using a highly efficient P‐chiral bisphosphine–rhodium complex in combination with ZnCl2 as the activator of the catalyst. The chiral γ‐secondary‐amino alcohols were obtained in 90–94 % yields, 90–99 % enantioselectivities, and with high turnover numbers (up to 2000 S/C; S/C=substrate/catalyst ratio)
已经开发了一种新的催化系统,该系统使用高效的P-手性双膦-铑配合物与ZnCl 2作为催化剂的活化剂,对β-仲氨基酮进行不对称加氢。手性γ-仲氨基醇的产率为90-94%,对映选择性为90-99%,并且具有很高的周转率(最高2000 S / C; S / C =底物/催化剂比)。在NMR光谱和HRMS研究的基础上,已经提出了ZnCl 2对催化体系的促进作用的机理。该方法已成功应用于三种重要药物(S)-度洛西汀,(R)-氟西汀和(R)-atomoxetine,高收率且具有出色的对映选择性。
Process for preparing (±)trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine
申请人:Foguet Rafael
公开号:US06881845B2
公开(公告)日:2005-04-19
The present invention relates to a process for preparing (±)-trans-4-p-fluorophenyl-3-hyroxymethyl-1-methylpiperdine of formula (I). The present invention also relates to novel intermediates of the formula (IX) and (IX′) methods for preparing said intermediates and the use of said compounds for preparing Paroxetine and Omiloxetine.